GW Pharmaceuticals (NASDAQ:GWPH) has filed a supplemental marketing application in the U.S. seeking approval to use Epidiolex (cannabidiol) oral solution to treat seizures associated tuberous sclerosis complex, a rare inherited disorder characterized by the growth on non-cancerous tumors in many parts of the body.
The FDA approved Epidiolex in June 2018 for Lennox-Gastaut syndrome and Dravet syndrome.
https://seekingalpha.com/news/3537202-gw-pharma-files-u-s-application-for-expanded-use-of-epidiolex
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.